An open competition to predict the progression of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease) disease from the largest database of ALS clinical trial data yields potential new biomarkers and algorithms that outperform human clinicians.
- Robert Küffner
- Neta Zach
- Melanie L Leitner
